{"entity":{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","aka":[],"tldr":"Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.","summary":"Kathy Albain is Vice Chair for Clinical Trials Partnerships at SWOG and Professor of Medicine at Loyola University Chicago. A breast and lung medical oncologist specialising in genomic assays, she led SWOG 8814, the study of Oncotype DX in node-positive disease, co-led RxPONDER (SWOG S1007), and chaired SWOG trials in stage III lung cancer. Her papers include a Lancet Oncology retrospective analysis of the prognostic and predictive value of the 21-gene recurrence score in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy and the New England Journal of Medicine report of the 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. Her record also links to TAILORx.","asOf":"2026-09-08","links":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albain%20KS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Kathy%20S.%20Albain"}],"tags":[],"related":[],"cancers":["breast-hr-positive","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["oncotype-dx"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":["rxponder","tailorx"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Vice Chair, Clinical Trials Partnerships, SWOG; Professor of Medicine, Loyola University Chicago","institutionId":"swog","specialisms":["Breast cancer","Lung cancer","Genomic assays"],"profiles":[{"label":"SWOG leadership","url":"https://www.swog.org/about/leadership"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Albain%20KS%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Kathy%20S.%20Albain"}],"papers":[{"title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","journal":"Lancet Oncology","year":2010,"url":"https://doi.org/10.1016/S1470-2045(09)70314-6","doi":"10.1016/S1470-2045(09)70314-6"},{"title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2108873","doi":"10.1056/NEJMoa2108873"}]},"route":"/people/kathy-albain/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/"}],"company":[{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/"}],"trial":[{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/"},{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/"}]}}